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Objectives. We sought to determine whether 12,500 IU of 
unfractionated heparin given subcutaneously twice daily for 4 
months after percutaneous transluminai coronary angioplasty 
beneficially influences the subsequent rate of angiographic resten- 
osis and the incidence of clinical events. 
Background. Heparin has been shown to exhibit powerful 
antiproliferative effects against smooth muscle cells in several 
animal models. 
Methods. A randomized trial with blinded data analysis was 
undertaken to assess the effect of unfractionated subcutaneous 
heparin on angiographic restenosis after coronary angioplasty. 
After successful angioplasty, patients were randomized to receive 
no heparin or 12,500 IU of heparin given subcutaneously twice 
daily for 4 months. Quantitative coronary angiography was per- 
formed before angioplasty, immediately after angioplasty and at
follow-up ("early" [before 4 months] or electively [at 4 months]). 
Results'. The study group comprised 339 patients, 167 randomly 
assigned to receive heparin, 172 to receive no heparin. Repeat 
cardiac catheterization was performed in 90% of randomized 
patients. At early and elective restudy (mean 4.2 months), the 
mean -+ SD difference in minimal lumen diameter between the 
postangioplasty and follow-up measurement was -0.55 -+ 
0.58 mm for the no heparin group and -0.43 + 0.59 mm for the 
heparin group (p = NS). Clinical events during the follow-up 
period did not differ significantly between groups: fatal myocar- 
dial infarction (1 patient in each group), coronary bypass grafting 
(5 patients in each group), repeat angioplasty (12 in the no 
heparin, 6 in the beparin group), angina at 4-month assessment 
(33% in the no heparin, 32% in the heparin group). 
Conclusions. Long-term treatment with high dose subcutane- 
ous heparin (12,500 IU twice daily) for 4 months did not favorably 
influence angiographic or clinical outcome after coronary angio- 
plasty. 
(J Am CoU Cardiol 1995;26:947-54) 
Percutaneous transluminal coronary angioplasty is a widely 
accepted form of treatment for symptomatic coronary artery 
disease. The late restenosis rate of 30% to 60% (1-5) contin- 
ues to limit the longer term benefit of the procedure. 
The restenotic process is characterized by elastic recoil (up 
to 40%) and myointimal hyperplasia (6,7), which is initiated by 
migration of medial smooth muscle cells from the media to the 
intima (8), with proliferation there after phenotypic modula- 
tion of the migrating cells. Subsequent extracellular matrix 
makes up the bulk of the later (>1 month) restenotic lesion. 
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Experimental work in animal models (9-15) and from in vitro 
studies (16) suggests that heparin may inhibit changes in 
intimal smooth muscle cells and therefore influence the re- 
stenotic process. 
In a large North American (enoxaparin) trial (17), low 
molecular weight heparin was shown to have no effect on 
angiographic restenosis or clinical events. The present study, 
referred to as the Subcutaneous Heparin and Angioplasty 
Restenosis Prevention (SHARP) trial, was performed to assess 
the value of unfractionated calcium heparin in preventing 
restenosis after coronary angioplasty. 
Methods  
Study patients. All symptomatic patients who had under- 
gone successful coronary angioplasty (defined as visually as- 
sessed diameter stenosis <50% after angioplasty) for an 
angiographically proved narrowing in one or more coronary 
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arteries were considered for entry into the trial in three 
participating regional centers (Leicester, Liverpool and Pap- 
worth, England, United Kingdom). Patients with restenotic 
lesions, chronic occlusions or conduit lesions were not in- 
cluded. Ethical approval for the trial was granted by the 
appropriate committees at each participating center. 
Angioplasty procedure and follow-up angiography. All an- 
gioplasty procedures were performed by the femoral route 
with use of steerable, movable guide wire systems. Aspirin 
(300 mg) was given to all patients before the procedure; the 
use of calcium channel antagonists or beta-adrenergic blocking 
agents, or both, was determined by the physician in charge of 
the patient. After placement of the femoral rtery sheath all
patients received abolus of 10,000 IU of intravenous heparin. 
During prolonged procedures additional heparin (5,000 IU) 
was given after 1 h. After the procedure and immediately on 
the patient's return to the ward, intravenous administration of
heparin was begun at an initial dose of 1,000 IU/h. The dose of 
heparin was adjusted to maintain the activated partial throm- 
boplastin time ratio to 2.0 to 3.0:1 for up to 24 h. Balloon type 
and size, inflation pressure and duration of inflation were 
selected by each operator. 
Three coronary angiograms were obtained from each pa- 
tient: one immediately before and one immediately after 
coronary angioplasty and one at follow-up (either elective [at 4 
months] or "early," if clinically indicated). 
Data acquisition. Quantitative analysis was performed 
with use of the CardioTrace system, whose results have been 
shown (18) to correlate well with those of the Coronary 
Angiography Analysis System (CAAS) using phantoms. Essen- 
tially, orthogonal views of each lesion were taken and the exact 
positioning of the X-ray tube and table height noted. The 
angiograms obtained before and after angioplasty and at 
follow-up were taken in the same views. Before each angio- 
graphic sequence the contrast-free catheter was filmed and at 
the end of the procedure the distal 20 cm was cut and saved for 
subsequent micrometer measurement and calibration of the 
analysis system. Before the postangioplasty angiogram the 
guide wire was removed to avoid interference with automated 
edge detection. Lesion characteristics were also assessed qual- 
itatively. 
All angiographic analysis was performed at the core labo- 
ratory by a single operator who had no knowledge of the 
patient's group. Postangioplasty angiograms were examined 
for dissection defined according to the modified National 
Heart, Lung, and Blood Institute criteria, Intracoronary 
thrombus was defined as the presence of a filling defect within 
the lumen, surrounded by contrast material seen in multiple 
projections in the absence of calcium within the filling defect, 
the persistence of contrast material within the lumen or a 
visible embolization of intraluminal material downstream. 
The absolute values of stenosis minimal lumen diameter 
and reference diameter were measured by using the catheter 
tip as a scaling device. The reference measurement was taken 
from the "normal" coronary segment at the time of stenosis 
measurement to allow for change in the reference artery with 
time (19). The CardioTrace automatically adjusts for the 
catheter size as measured by the micrometer gauge. 
Treatment allocation. After successful coronary angio- 
plasty and on the patient's return to the ward, we sought he 
patient's consent o be included in this trial. Consent was 
sought at his time because this was a trial of successful 
angioplasty and subsequent restenosis. A total of 339 patients 
met all inclusion and exclusion criteria and gave informed 
written consent. A computer-generated program randomly 
assigned patients to receive ither no heparin (no injection) or 
unfractionated subcutaneous heparin (12,500 IU twice daily 
for 4 months). 
Patients randomized to the heparin group were given the 
injections 2 h after femoral sheath withdrawal. All patients 
were discharged receiving aspirin (75 to 300 mg daily) and 
calcium channel antagonists, nitrates and beta-adrenergic 
blocking agents according to operator choice. 
Follow-up evaluation. Patients receiving heparin treatment 
had a peak plasma heparin assay performed 1 week after 
discharge and a weekly platelet count for the 1st 4 weeks of 
therapy. Anticoagulation levels were not measured, because 
this is the level of heparin given long-term and safely in other 
groups of patients. 
A syringe count was performed at 2 and 4 months. If 
patients reported return of their angina within the 4-month 
follow-up period, coronary angiography was performed if the 
physician deemed it clinically indicated. Even if there was no 
evidence of restenosis patients were not required to undergo 
further catheterization at4 months. 
On admission for the 4-month elective catheterization, 
patients underwent a standard treadmill exercise test (Bruce 
protocol). End points for the test were the occurrence of 
anginal chest pain, decrease in systolic blood pressure, signif- 
icant arrhythmia, or ST segment depression >1 mm 80 ms 
after the J point. Clinical status was assessed during the 
in-hospital admission for repeat catheterization. 
End points. The primary end point of the SHARP trial was 
the within-patient change in minimal lumen diameter as 
determined by quantitative angiography. Postangioplasty val- 
ues were obtained from the last postangioplasty angiogram 
after withdrawal of the guide wire. For patients admitted early 
who underwent repeat angioplasty, the angiogram preceding 
repeat balloon dilation was considered the follow-up angio- 
gram and was recorded in exactly the same views used in the 
angiograms previously obtained immediately before and after 
angioplasty. For all other patients the planned follow-up 
angiogram was used. 
Secondary end points were death, myocardial infarction, 
need for coronary artery bypass urgery and repeat coronary 
angioplasty. The presence and severity of angina at follow-up 
(early or elective) were assessed according to the Canadian 
Cardiovascular Society classification. 
Statistical analysis. Calculations for the power of any 
restenosis trial are based on an arbitrary assessment of the 
biologic goal balanced by the side effects of the medication 
being tested. In an attempt to objectively determine the sort of 
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Figure 1. Patient flow from time of randomization to 
follow-up for the no heparin and heparin groups. 
"Early" and elective = cardiac catheterization per- 
formed, respectively, before 4 months and at the 
scheduled 4-month follow-up time. 
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effect we might achieve with heparin, we tested, in a pretrial 
study, the plasma of patients given the study dose of heparin 
(12,500 IU twice daily) against human smooth muscle cell 
growth in vitro. We found a 35% reduction in smooth muscle 
cell growth over 10 days (from 6.9 x 104 to 4.5 x 104) when 
these cells were exposed to blood from patients treated with 
heparin (mean level 0.3 IU/ml). Because this level of reduction 
is approximately equal to the arbitrarily used 33% reduction 
deemed important by other trialists, we used it as the aim of 
the treatment arm. On the basis of this 35% reduction and the 
results of Nobuyoshi et al. (20) and Serruys et al. (3), we 
estimated that the mean _+ SD loss in minimal umen diameter 
over a 4- to 6-month period in control patients would be 
-0.50 - 0.5 mm. Assuming that diameters are normally 
distributed (21), we calculated that to show a reduction (the 
anticipated loss of lumen diameter by- 35% in the heparin- 
treated group), 129 patients with complete angiographic fol- 
low-up were required in each group to give a power of 80% at 
an alpha level of 0.05. To allow for medical withdrawal of 
patients and patients defaulting from the trial, we aimed to 
recruit 340 patients. A total of 339 patients who had had 
successful angioplasty were recruited. 
Results  
Patient numbers. From February 1990 to the end of June 
1993, 370 patients who had undergone successful coronary 
angioplasty were approached for participation in the SHARP 
trial. A total of 339 patients (92%) consented to participate; of 
these, 167 patients (189 lesions) were randomly assigned to 
receive subcutaneous heparin (12,500 U twice daily) and 172 
patients (188 lesions) to receive no heparin. During the trial 
period 40 patients defaulted from the trial (27 in the heparin 
and 13 in the no heparin group); 39 patients required "early" 
cardiac catheterization (23 in the no heparin and 16 in the 
heparin group). Figure 1 shows the patient flow from the time 
of randomization to follow-up. 
Baseline characteristics and clinical follow-up. Tables 1 
and 2, respectively, show the demographic data for the two 
groups after default and lesion characteristics before and after 
default. The baseline characteristics of both groups were w ll 
matched. Clinical follow-up data were available from all pa- 
tients not defaulting from the trial. During the course of the 
Table 1. Patient Characteristics of the No Heparin and Heparin 
Groups After Default of 40 Patients 
No Heparin Group Heparin Group 
(159 pts, 174 lesions) (140 pts, 161 lesions) 
Men (%) 82 80 
Age (yr) (mean ± SD) 56.2 _+ 7 56.7 _+ 
Smoker 48 56 
Diabetes l 1 7 
Hypertension 31 26 
Hyperlipidemia 29 26 
Previous MI 71 64 
Previous CABG 6 3 
Previous PTCA 3 4 
Drug therapy 
Aspirin 122 109 
Calcium antagonists 106 101 
Nitrates 104 91 
Beta-blockers 102 96 
Angina grade 
0 0 0 
1 4 3 
2 81 73 
3 55 49 
4 19 15 
Duration of angina (too) 
<6 40 41 
6-12 53 42 
12-24 21 18 
>24 45 39 
Unless otherwise indicated, ata are xpressed asnumber of patients. 
CABG = coronary artery bypass grafting; MI = myocardial nfarction; PTCA = 
percutaneous transluminal coronary angioplasty; pts = patients. 
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Table 2. Vessel and Lesion Characteristics of the Heparin and No 
Heparin Groups Before andAfter Default 
No Heparin Group Heparin Group 
Pro Post Prc Post 
Vessels 188 174 189 161 
Vessel dilated 
LAD 100 t)5 100 87 
RCA 46 42 49 40 
LCx 42 37 40 34 
Sites dilated (no.) 
1 160 15[I 150 124 
2 12 10 15 14 
3 0 ~1 3 3 
4 1 1 0 0 
Lesion characteristic 
A 64 5~ 67 57 
B 97 91 104 92 
C 27 24 18 12 
Dissections (no.) 38 33 34 27 
Dissection grade 
A 14 12 10 9 
B 13 13 12 9 
C 9 7 10 8 
D 2 1 2 1 
E 0 II 0 0 
Reference artery./ 0.96/0.17 l i .17~0.2 0.911/0.14 1.11/0.2 
balloon ratio 
Unless otherwise indicated, data are expressed as number of vessels. LAD : 
left anterior descending coronau artet3': LCx left circumflex corona U artew: 
Pre (Post) - before (after) default: RCA - right corona U artery. 
Table 3. Minimal Lumen Diameters 
of Patients Undergoing "Early" (<4 
Cardiac Catheterization 
and Clinical Outcome 
too) Repeat 
No Heparin Group Heparin Group 
(n - 23) (n - 16) 
Reference diameter (mm) 
Prc PTCA 2.81 _+ 0.56 2.71 _+ 0.50 
Post PTCA 2.86 _+ 0.49 2.69 _+ 0.55 
Follow-up 2.76 + 0.46 2.76 _+ 0.55 
Minimal lumen diameter (mm) 
Pre PTCA 0.68 -+. I).42 0.78 -+ 0.31 
Post PTCA 1.78 -+ 0.42 1.76 -+ 0.48 
Follow-up 0.96 + 0.71 1.18 + 0.59 
c.; diameter reduction 
Pre PTCA 75.3 -+ 15 72.3 -+ 10 
Post PTCA 37.1 + 14 34.5 _+ 1l 
Follow-up 64.6 + 25 57.3 -+ 20 
Angina grade (CCS class) 
Mean 2.6 2.6 
Range 2-4 1-4 
Repeat catheterization at (wk) 
Mean 8.5 7.5 
Range 1-14 0.5-12 
Repeat PTCA 12 6 
CABG 5 5 
Medical therapy 6 5 
Unless otherwise indicated, data are presented as number of patients or 
mean value = SD. CCS class = Canadian Cardiovascular Society classification; 
other abbreviations a in Tables I and 2. 
study two patients (one patient in each group) died, both of 
myocardial infarction. Ten patients (5 in each group) under- 
went coronary bypass urgery and 18 (12 in the no heparin and 
6 in the heparin group) had repeat coronary, angioplasty. At 
the 4-month assessment, 33g4 of patients in the no heparin and 
32% of those in the heparin group reported recurrent angina. 
Angiographic analysis. During the study period, 39 pa- 
tients underwent "early" cardiac atheterization because angi- 
nal symptoms had recurred (23 patients in the no heparin 
group and 16 in the heparin group). Table 3 shows the 
reference diameters, minimal lumen diameters, restenosis 
rates and clinical outcome of the patients undergoing early 
catheterization. The minimal umen diameters before and after 
coronary angioplasty and at follow-up were not significantly 
different at any time between the two patient groups. As 
assessed by a definition of "loss of 50c,~ of the absolute gain," 
19 patients in the no heparin and 9 in the heparin group had 
restenosis, (chi-square test, p - (t.15, odds ratio 0.27, 95q2 
confidence interval [C1] -0.06 to 1.2). There were no signifi- 
cant differences in restenosis rates or changes in minimal 
lumen diameter between patients with early or elective follow- 
up angiography. 
Figure 2 shows the quantitative angiographic details of the 
two groups at elective follow-up. For those patients undergoing 
elective repeat coronary angiography, the difference between 
the minimal lumen diameter at follow-up and immediately 
after angioplasty was 0.49 + 0.57 mm in the no heparin 
group and -0.41 _+ 0.57 mm in the heparin group. The 
0.88-mm difference--that is, the treatment effect--was not 
significant (p = 0.22, 95% CI -0.05 to 0.22). As assessed by a 
categoric definition of loss of 50% of the absolute gain, the 
restenosis rate was 46% in the no heparin and 39% in the 
heparin group (chi-square test, p = 0.32, odds ratio 0.75, 95% 
CI 0.46 to 1.2). For all patients (those with early and elective 
restudy), the loss at follow-up in minimal lumen diameter was 
-[).55 +_ (1.58 mm for the no heparin and -0.43 _+ 0.59 mm in 
the heparin group (Table 4). The overall treatment effect was 
0.12 mm (p - 0.07, 95% CI -0.004 to -0.25 mm), which 
corresponded to a restenosis rate of 51% in the no heparin and 
41c:~ in the heparin group (p = 0.09). 
Figures 3 and 4 represent a cumulative frequency curve of 
the minimal umen diameter and a plot of relative loss versus 
relative gain for the two groups. 
Treadmill exercise tests. At follow-up 85% of patients in 
the no heparin and 86% of those in the heparin group 
underwent a standard treadmill exercise test (Bruce protocol). 
There were no differences between groups in the number of 
patients reporting pain or having significant STchanges during 
the test. 
Acceptability of heparin treatment. The number of pa- 
tients randomized into the study represents 92% of the pa- 
tients approached. The main reason for nonenrollment was 
unwillingness to self administer heparin. Indeed, the major 
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reason for default was the inconvenient nature of the treat- 
ment. Three patients were withdrawn from the study as a result 
of pruritic swellings at the site of the injections that resolved on 
discontinuation f treatment. No cases of thrombocytopenia 
were reported and the occurrence of osteoporosis in one 
patient in each group is of doubtful significance. Apart from 
two instances of bleeding at the femoral puncture site, no 
patients reported spontaneous bruising or troublesome h ma- 
toma formation after minor trauma. The treatment, although 
onerous, would appear to be safe and generally well tolerated. 
Table 4. Absolute Measurements of Reference Diameters and 
Obstruction Diameters for All Patients Undergoing 
Repeat Catheterization 
No Heparin Group Heparin Group 
(159 pts, 174 lesions) 1141) pts, 161 lesions} 
Reference diameter (ram) 
Pre PTCA 2.82 : 0.54 2.87 + 0.54 
Post PTCA 2.81 + 0.50 2.87 ± 0.51 
Follow-up 2.81 + 0.50 2.87 _+. 0.52 
Minimal lumen diameter (mm) 
Pre PTCA 0.83 ~ 0.37 0.81 + 0.34 
Post PTCA 1.91 + ().4~ 1.88 ± 0.48 
Follow-up 1.36 t 0.63 1.45 + 0.64 
Acute gain (mm) 1.08 ± 0.48 I.I)7 + 0.49 
Relative gain 0.39 ": 0.18 0.38 + 0.15 
Late loss (mm) 0.55 + 0.58 0.43 ± 0.59 
Relative loss 0.2/) ~ 0.22 11.15 ± 021 
Net gain index 0.19 + 0.22 0.22 _+ 0.20 
Percent stenosis 
Pre PTCA 71.5 + 12'~ 71.9 ± 10o~ 
Post PTCA 3L6 + 13o~ 35.4 + 12"'4 
Follow-up 52./) + 21% 50.0 + 19o~ 
Restenosis rate (loss 5tl9~ 
absolute gain) 
Patients 5 Vc 41 c:~ 
Vessels 48r; 39~ 
Unless othe~'ise indicated, data are expressed as mean value _+ SD. 
Abbreviations as in Tables 1 and 2. 
Discussion 
Although the effects of heparin on smooth muscle cell 
proliferation have been known for some time, the precise 
mode of action is unclear. Heparin binds to smooth muscle 
cells and is taken up by both receptor-mediated and slower 
endocytotic pathways (22). Studies utilizing ornithine decar- 
boxylase activity and tritiated thymidine uptake suggest that 
heparin acts either at the late G1 or early S phase of the cell 
cycle, with consequent reduction in synthesis of deoxyribonu- 
cleic acid and ribonucleic acid (23). Heparin may also have 
secondary effects due to a reduction in expression of growth 
factor eceptors (24), or enhanced action of growth inhibitory 
factors (25) such as transforming growth factor B. 
There are few studies in humans addressing the effect of 
heparin on restenosis after coronary angioplasty. The trial by 
Ellis et al. (26), randomly assigned 416 patients to receive 
either intravenous heparin or dextrose for 18 to 24 h after 
coronary angioplasty. The restenosis rates were 41.2% in the 
heparin group and 36.7% in the control group when assessed at 
6 months (restenosis defined as >50% diameter stenosis at 
follow-up). Similar results were obtained by Saenz et al. (27), 
although their study had considerably fewer patients. For 
similar reasons little meaningful data could be derived from 
the study by Lehmann et al. (28), which was terminated early 
on ethical grounds because 82% of the 23 patients at follow-up 
had restenosis. More data are available from the Enoxaparin 
study (17) involving 465 patients who were randomized tolow 
molecular weight eparin (30 mg subcutaneously daily) or 
placebo for 1 month. As assessed from clinical end points, the 
restenosis rate was 51% in the treatment group and 49% in the 
control group. There was no significant difference in the 
change in minimal umen diameter at follow-up (0.49 and 
11.5 mm, respectively, for the control and the treatment 
groups). 
There has been some debate as to whether the commer- 
cially available low molecular weight heparin contains all of the 
antiproliferative effects of the subfractions outlined in the 
publications by Guyton et al. (10) and Hoover et al. (29). 
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Figure 3. Cumulative frequency urves of minimal 
lumen diameters for the heparin (triangles) andno 
heparin (circles) groups before and immediately 
after coronary ngioplasty and at follow-up. 
Commercially available lowmolecular weight heparin may not 
be the same subfraction as that used in experimental models. 
For this reason we chose to examine the effects of unfraction- 
ated heparin, knowing also that any retained antithrombotic 
effects of the unfractionated heparin may lso be beneficial if 
thrombus formation is another smooth muscle cell stimulus 
(30). We chose to give the heparin for a total of 4 months 
because data suggest that 90% of restenosis f it is to occur will 
occur within this time. Although the process of smooth muscle 
cell proliferation takes place in the first few days, we chose not 
to risk merely delaying the process by limiting the time of 
heparin administration to this period. 
Despite the advantages ofusing this relatively high dose of 
unfractionated heparin given over the known course of the 
restenotic process, we have shown that this treatment failed to 
beneficially influence either the angiographic outcome 
(amount of intimal hyperplasia) or the clinical outcome. There 
may have been several reasons for these findings. 
Figure 4. Plot of relative loss versus relative gain for the heparin (plus 
signs) and no heparin (circles) groups. 
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Study power. Currently the power of any trial is deter- 
mined by the effect one wants to achieve (31). Thus a 10% 
reduction requires larger numbers than if a 50% reduction is
the aim. The use by other investigators of a 33% reduction 
(resulting in trial numbers of 230 patients/group) is as arbitrary 
as any other present reduction. Our choice was based on in 
vitro studies. However, for the secondary end points (clinical 
outcome) the study power was too small. 
Heparin dose. The dose of heparin selected for this trial 
was based on both ethical and pharmacologic considerations. 
At the time of the study's inception, the largest available dose 
of "ready to use" heparin was 12,500 IU. Our dose of 25,000 
IU of heparin daily approaches doses that could result in a 
significant risk that patients would develop osteoporosis (32). 
Additionally, the statements of patients interviewed before the 
trial, but not part of it, indicated that asking patients to 
self-inject this drug more than twice daily would be unaccept- 
able. 
From our own laboratory work using cultured human 
smooth muscle cells we found that concentrations of heparin 
that could be achieved by subcutaneous injection of 12,500 IU 
(i.e., 0.3 IU/ml), significantly inhibited smooth muscle cell 
proliferation. Castellott et al. (33) have shown that 1 to 5/~g of 
heparin added to growth media could produce inhibition of 
smooth muscle cells in culture. However, in vivo work suggests 
that higher doses are required to produce a significant inhibi- 
tion of smooth muscle cell proliferation. Clowes and Kar- 
novsky (9), using the rat carotid model, reported that 50 to 
100 IU/kg body weight per h was needed to produce significant 
inhibition of cell proliferation. Likewise, using hypercholester- 
olemic rabbits, Currier et al. (13) showed that 10 mg/kg per day 
of enoxaparin could reduce the restenosis rate in iliac arteries, 
but human studies (17) using 30 mg/day showed nobenefit. 
Thus, although we used the largest ethically acceptable 
dose, this dose may have been too small to locally inhibit 
smooth muscle cell proliferation. There has been a suggestion, 
perhaps a justification of negative results, hat humans are 
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more sensitive than animals to many of the drugs tried 
systemically, and thus the dosage issue is not relevant. How- 
ever, in the light of our results, it is reasonable to conclude that 
human vascular smooth muscle cells are no more sensitive than 
animal smooth muscle cells to the effects of heparin; otherwise, 
some beneficial effect ought to have been observed with this 
smaller dose. 
Conclusions. The failure of unfractionated heparin to 
show any benefit in humans despite encouraging results in 
animal models is similar to the outcome of trials with cilazapril 
(34), enoxaparin (17) and ketanserin (35). The ability of 
heparin to inhibit vascular smooth muscle cell growth in vitro 
and in animal models of vascular injury is well documented. It 
appears not to have the therapeutic efficacy to reduce resten- 
osis after angioplasty in humans. The published results of 
intravenous short-term administration (24 to 48 h) of heparin 
and the results of medium-term (1 month) of low molecular 
weight heparin also show no benefit. The reasons for these 
findings have been addressed by other trialists studying other 
drugs, namely the discrepancy between systemic doses that 
work in animals and those that can be given to humans. The 
argument that smooth muscle cells or the mechanisms stimu- 
lating them are more sensitive in humans appears not to hold. 
Although we undertook a study with heparin given in as large 
a dose that was believed to be safe and ethical, it is clear that 
attention will need to be turned to methods of local delivery 
that will permit administration of doses that affect the process 
without adversely affecting the patient. Perhaps before heparin 
is finally rejected as a "magic bullet" for the prevention of 
restenosis, clinical trials should be conducted that match 
animal studies with continuous infusions or by local targeted 
delivery. 
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Appendix 
Definitions of Lesion Characteristics and Dissection 
Grades (Table 2) 
Lesion Characteristics 
Type A: Small radiolucent area within the lumen of the vessel 
disappearing with the passage of the contrast material. 
Type B: Contrast extravasation parallel to the lumen of the vessel 
disappearing with the passage of the contrast material. 
Type C: Contrast extravasation persisting after passage of the contrast 
material. 
Type D: Spiral-shaped filling defect with normal (DI) or delayed (D2) 
anterograde flow. 
Type E: Persistent lumen filling defect with delayed runoff of the 
contrast material in the distal vessel. 
Type F: Filling defect accompanied by total occlusion. 
Dissection Characteristics 
Type A: Discrete, concentric, readily accessible, smooth contour, 
nonangulated segment, no calcification, not occlusive, not ostial, 
no major branch involvement, absence of thrombus. 
Type B: Tubular, eccentric, moderate tortuosity, moderately angulated 
segment, irregular contour, moderate calcification, total occlusion 
<3 months, ostial site, bifurcation lesion, thrombus present. 
Type C: Diffuse, very tortuous, markedly angulated, total occlusion >3 
months, inability to protect side branch. 
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